K
19.78
0.18 (0.92%)
| Penutupan Terdahulu | 19.60 |
| Buka | 19.74 |
| Jumlah Dagangan | 236,919 |
| Purata Dagangan (3B) | 322,063 |
| Modal Pasaran | 1,428,147,712 |
| Harga / Jualan (P/S) | 3.85 |
| Harga / Buku (P/B) | 3.35 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2024 |
| Margin Keuntungan | -2.36% |
| Margin Operasi (TTM) | -8.61% |
| EPS Cair (TTM) | -0.120 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 67.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.42% |
| Nisbah Semasa (MRQ) | 3.24 |
| Aliran Tunai Operasi (OCF TTM) | 11.24 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 25.74 M |
| Pulangan Atas Aset (ROA TTM) | -3.16% |
| Pulangan Atas Ekuiti (ROE TTM) | -2.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | Kiniksa Pharmaceuticals, Ltd. | Menaik | Menaik |
AISkor Stockmoo
1.4
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -4.0 |
| Purata | 1.38 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 4.10% |
| % Dimiliki oleh Institusi | 97.97% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 40.00 (JP Morgan, 102.22%) | Beli |
| Median | 37.50 (89.59%) | |
| Rendah | 35.00 (Evercore ISI Group, 76.95%) | Beli |
| Purata | 37.50 (89.59%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 22.52 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 05 Nov 2024 | 40.00 (102.22%) | Beli | 22.03 |
| Evercore ISI Group | 30 Oct 2024 | 35.00 (76.95%) | Beli | 23.01 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Jan 2025 | Pengumuman | Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance |
| 06 Jan 2025 | Pengumuman | Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference |
| 26 Nov 2024 | Pengumuman | Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference |
| 12 Nov 2024 | Pengumuman | Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference |
| 29 Oct 2024 | Pengumuman | Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution |
| 28 Oct 2024 | Pengumuman | Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis |
| 22 Oct 2024 | Pengumuman | Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |